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Equine inflammatory airway disease (IAD) and recurrent airway obstruction (RAO) represent a spectrum of chronic inflammatory
disease of the airways in horses resembling human asthma in many aspects.Therefore, both are now described as severity grades of
equine asthma. Increasing evidence in horses and humans suggests that local pulmonary inflammation is influenced by systemic
inflammatory processes and the other way around. Inflammation, coagulation, and fibrinolysis as well as extracellular remodeling
show close interactions. Cytology of bronchoalveolar lavage fluid and tracheal wash is commonly used to evaluate the severity of
local inflammation in the lung. Other mediators of inflammation, like interleukins involved in the chemotaxis of neutrophils, have
been studied. Chronic obstructive pneumopathies lead to remodeling of bronchial walls and lung parenchyma, ultimately causing
fibrosis. Matrix metalloproteinases (MMPs) are discussed as the most important proteolytic enzymes during remodeling in human
medicine and increasing evidence exists for the horse as well. A systemic involvement has been shown for severe equine asthma by
increased acute phase proteins like serum amyloid A and haptoglobin in peripheral blood during exacerbation. Studies focusing
on these and further possible inflammatory markers for chronic respiratory disease in the horse are discussed in this review of the
literature.
1. Introduction
Disorders of the respiratory system, particularly the lower air-
ways, are the most frequently diagnosed conditions in sport
horses evaluated for poor performance [1, 2]. Equine recur-
rent airway obstruction (RAO) and IAD represent a spectrum
of chronic inflammatory disease of the airways in horses
resembling human asthma in many aspects [3–5]. Therefore,
the term equine asthma has been suggested to include
inflammatory airway disease (IAD) as mild-to-moderate and
recurrent airway obstruction (RAO) as severe equine asthma
[5]. Parallels of human and equine disease are shown in
Table 1. RAO and IAD are characterized by the absence of
signs of acute infection like fever or leukocytosis, duration of
more than 4 weeks, neutrophilic inflammation in bronchial
secretion, airway hyperresponsiveness, and subclinical versus
reversible airway obstruction [3, 6]. While human asthma
has been commonly described as an eosinophilic disease,
it is lately more and more recognized that neutrophilic
inflammation may be present in human asthma of all sever-
ities as well, in particular in severe asthmatic patients and
during acute disease exacerbation [7–9]. On the other hand,
eosinophils, metachromatic cells, or neutrophils characterize
the subforms of mild-to-moderate equine asthma or IAD
[3]. IAD often occurs coincidentally with exercise-induced
pulmonary hemorrhage (EIPH) in racehorses [10–13]. The
later does not have an allergic background, but inflammation
following stress failures of pulmonary capillaries may be a
trigger factor for the development of IAD in these subjects.
IAD and EIPH also play a role in warmbloods; nevertheless,
the most common lower airway disease in these horses is
RAO. The estimated prevalence in the northern hemisphere
is about 14% [6] with incidence and severity of the disease
increasing with age and stabling, so that RAO is a common
reason for the career’s end of sport horses [14]. Due to the fact
that RAOwas much better defined over the last 20 years than
IAD, literature on equine asthma mainly focused on RAO.
Although an increased risk for IAD horses to develop RAO
Hindawi Publishing Corporation
Mediators of Inﬂammation
Volume 2016, Article ID 5693205, 11 pages
http://dx.doi.org/10.1155/2016/5693205
2 Mediators of Inflammation
Table 1: Parallels and differences between equine and humane asthma. IAD = inflammatory airway disease, RAO = recurrent airway




(RAO) Mild human asthma Severe human asthma
Airway hyperresponsiveness Yes Yes Yes Yes
Airway obstruction Subclinical Partly reversible Reversible Partly reversible
Environmental origin Yes Yes Yes Yes
Genetic origin No data Yes Yes Conflicting evidence
ASM dysfunction No data Yes Yes Yes
ECM remodeling Conflicting evidence Yes Yes Yes
Airway neutrophilia Neutrophilic subtype Yes Neutrophilic endotype Yes
Airway eosinophilia Eosinophilic subtype No Yes Yes
has been described, most horses seem to recover. Therefore
it is essential not to use equine asthma as a general term for
both diseases but to be aware of the differentiation between
mild-to- moderate (IAD) and severe equine asthma (RAO).
Since bronchoalveolar lavage (BAL) using fiber-optic
endoscopy was first described in horses [15], cytological
and microbiological evaluation of tracheal washes (TW)
and BAL fluid (BALF) have become the cornerstones in
the diagnosis of respiratory disease alongside clinical and
functional examinations. Although severely asthmatic horses
often show easily visible signs of disease, difficulties may
arise in clinical practice due to the fact that patients may
be presented in remission. Mild-to-moderate equine asthma
tends to occur subclinically as well. A natural challenge test
including exposure of horses to mouldy hay and straw is
recommended for research purposes to differentiate between
mild-to-moderate and severe forms of equine asthma, but not
for clinical routine [3].
In these cases, commonly used examination techniques
may be insufficient for diagnosis and evaluation of treatment
success. Therefore, multiple studies have been performed
to establish further inflammatory markers for equine res-
piratory disease. Evidence exists that systemic involvement
may exist in severe equine asthma as has been shown
for human asthma [16] and chronic obstructive pulmonary
disease (COPD) [17, 18]. Therefore, not only markers for
pulmonary inflammation dominated by neutrophils, but also
systemic markers in peripheral blood may be rewarding in
the evaluation of equine disease.
2. Local Inflammatory Markers in
TW and BALF
Neutrophilia in TW and BALF is a predominant cytological
feature of inflammation in mild-to-moderate and in partic-
ular in severe equine asthma [19–22], in which neutrophils
migrate within hours into the airway lumen, followed by
the development of airway obstruction and a late phase of
migration [22–24]. Neutrophil recruitment to the airway
lumen also occurs in acute asthma exacerbations as early as
4 hours after allergen challenge [25–27]. Reference values
for BALF cytology in healthy include a total nucleated cell
count ≤ 530 cells/lL, neutrophils ≤ 5%, eosinophils ≤ 1%,
and metachromatic cells ≤ 2% based on a 250mL infusion
volume [3]. In exacerbations of severe equine asthma or
RAO horses present with dyspnea at rest, as shown by
a maximum interpleural pressure > 15 cmH
2
O caused by
bronchoconstriction, mucosal swelling and mucus accumu-
lation [6], and inflammation of the small airways, in which
neutrophils exceed 25% in BALF cytology [28].The definitive
diagnosis of IAD is also based on BALF cytology [3], which is
characterized by an increase in the total nucleated cell count
withmild neutrophilia [29–32] and lymphocytosis [31, 33, 34]
or, alternatively, by increased mast cell [35, 36] or eosinophil
counts [37].
The immunologic background of severe equine asthma
remains not fully elucidated despite many studies on the
pathogenesis [38–41] and the therapeutic approach to exac-
erbation [42–53]. Although evidence for aTh-2 based hyper-
sensitivity reaction of allergy type IV tends to overwhelm
[54–56], there is also evidence for aTh-1 based immunologic
background of the disease. Increased levels of interleukins 4
and 5 as well as decreased Interferon-𝛾 expression support
a Th-2 base [56]. Lavoie et al. [54] showed that recombi-
nant equine IL-4 causes morphological changes in blood
neutrophils, increases IL-8 mRNA levels, and potentiates
effects of LPS and TNF-𝛼 on IL-8 expression by pulmonary
artery endothelial cells. Receptors for IL-4, however, were not
increased on neutrophils in severe equine asthma compared
to healthy horses, but a genetic linkage of polymorphisms
in IL-4-receptor-𝛼 on chromosome 13 with severe equine
asthma was found and increased expression of this receptor
in one high-prevalence family of horses, but not in another
one [57]. On the other hand, Ainsworth et al. [38] demon-
strated increased interferon-𝛾 production in BAL cells, which
supports a Th1-based background for RAO, while still others
suggest no involvement of either type response in this disease
[58]. Inhalation of immune modulatory, specific bacterial
DNA-sequences (CpG-nanoparticles) modified the profile of
expressed cytokines in RAO patients towards a Th-1 profile
and was accompanied by a marked reduction in clinical
signs and neutrophilia in TW [59]. IL-8 is the predominant
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chemokine for neutrophils and was shown to be increased
in BALF within hours after changing roughage feed from
grass silage to hay in RAO affected horses [60]. In chronic
inflammation IL-17 [61] and IL-1𝛽 and IL-23 also play a role
[62].
While the percentage of neutrophils in BALF decreases
to reference levels in phases of remission, which hinders
cytological diagnosis of the disease, myeloperoxidase (MPO)
concentration in BALF was significantly higher in severe
equine asthma during either crisis or remission compared to
control horses [63]. Therefore, MPO may serve as a sensitive
inflammatory marker in subclinical cases [64]. In unison
to this, several studies demonstrated reduced antioxidative
capacity in severe equine asthma as evidenced by low ascorbic
acid concentrations in BALF [65–69]. During recovery from
exacerbation, the reduction in ascorbic acid is followed by
an increase in BALF glutathione peroxidase activity, presum-
ably to combat disease-associated oxidative stress [65, 66].
Furthermore, markers of oxidative stress have been identified
within the airways and in exhaled breath condensate in severe
equine asthma, but not following short-term organic dust
inhalation challenge [56, 68].
3. Systemic Inflammatory Markers
in the Blood
Pulmonary neutrophilic inflammation during exacerbation
has been the focus of many studies. It is largely reversible
by antigen withdrawal in a low-dust environment [6, 28].
However, as in neutrophilic human asthma [70], evidence
exists that the inflammatory processes are not completely
resolved as residual airway bronchoconstriction, elevated
smooth muscle cell turnover surrounding the airways, and
higher nuclear factor 𝜅B (NF-𝜅B) activity are observable
in asymptomatic horses affected with severe equine asthma
[4, 71, 72]. NF-𝜅B is a specific transcription factor that has
a key role in inflammatory processes. It also plays a role in
airway smooth muscle (ASM) cells phenotype modulation,
characterized by reversible switching between contractile and
proliferative phenotypes, which is considered to contribute
to airway proliferation in human asthma [7]. NF-𝜅B has
also been reported as a key regulator for the occurrence and
development of equine asthma. During disease exacerbation,
peripheral blood leucocyte activation and increased con-
centration of circulatory inflammatory mediators have been
observed in affected horses, suggesting that the inflammatory
process might not be limited to the lung [73–77]. Human
asthma is considered to be a systemic disease, as an increase
in several inflammatory markers has been observed in the
blood of affected patients [16]. These include immunity-
related mediators (cytokines, eicosanoids, cyclooxygenase
products, and IgEs) and the acute phase markers C-reactive
protein, haptoglobin, fibrinogen, and serum amyloid A [78–
80]. Systemic inflammation in patients with chronic airway
diseases is thought to contribute to comorbidities [16, 81–84].
Literature on systemic inflammatory processes in equine
asthma is rare. Lavoie-Lamoureux et al. [85] compared
several acute phase proteins (haptoglobin, serum amyloid
A, and C-reactive protein) and cytokines (interleukins 2, 4,
and 10 as well as interferon-𝛼 und interferon-𝛾) in serum
of healthy individuals and horses affected by severe equine
asthma over 30 days of exposition to hay and straw. Hap-
toglobin was found to be a suitable marker for both acute and
chronic systemic inflammation, whereas high concentrations
of serum amyloid A indicated acute inflammation. There
was no difference in serum concentrations of the evaluated
cytokines between affected horses and controls. In another
study though, increased TNF-𝛼 concentrations were found
after ex vivo stimulation with bacterial products in severe
equine asthma [86]. Niedz´wiedz´ et al. [87] found increased
markers for oxidative stress in peripheral blood during
exacerbation compared to controls. Although these systemic
markers seem to be attractive, as repeated cytological exam-
inations from bronchoalveolar lavage samples may not be
necessary anymore, they might be hard to use in a clinical
setting. Due to their low specificity for pulmonary disease,
further unrelated and possibly subclinical disease might have
to be excluded, leading to a higher diagnostic effort in the end.
As bronchoalveolar lavage is an easy-to-perform procedure
in a standing sedated horse, markers from this fluid may
be of higher value, in particular in mild-to-moderate equine
asthma or disease remission.
Since the 1970s a correlation of sepsis and hypocal-
cemia has gained increasing attention in research. In sepsis,
procalcitonin (PCT) is found in high concentration in the
peripheral blood and is expressed by many organ tissues
[88]. PCT is a precursor of the hormone calcitonin, which
regulates calcium metabolism by inhibition of osteoclasts’
activity. In healthy subjects, preprocalcitonin (pre-PCT) is
produced exclusively in the thyroid gland. PCT plasma
concentrations in acute local inflammatory processes in the
lung are much lower than in sepsis but allow differentiation
between pulmonary diseases in humans [89–91]. For exam-
ple, PCT was used for differentiation of tuberculosis from
other pneumopathies [92]. In chronic pulmonary disease
like human asthma, increased PCT concentrations were
found as well. Acute exacerbations are often accompanied by
bacterial infections of the lower airways. PCT can be used
in the decision for or against antibiotic treatment and may
help to interpret diffuse thoracic radiographs [93, 94]. In
COPD (chronic obstructive pulmonary disease) PCT eases
the decision for antibiotics or glucocorticoids [95]. It is also
useful for follow-up in COPD [96].
Rieger et al. [97] established an ELISA specific for equine
PCT. Clear differences were found in plasma between septic
horses and healthy individuals using this and another ELISA
[98, 99]. Increases in systemic PCT concentrations were also
found in chronic pneumopathies compared to horses free
of respiratory disease in BALF and a trend was also visible
in plasma, although this needs to be confirmed in a higher
number of samples [100].
4. Coagulation and Fibrinolysis
In the long term, chronic obstructive pneumopathies lead to
chronic remodeling of bronchial walls and lung parenchyma,
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which is accompanied by fibrosis formation [101–104]. This
remodeling is favored by procoagulatory conditions, while
fibrinolysis serves to remove alveolar fibrin deposits and
counteracts coagulation and beginning fibrosis [105].
After mechanical and inflammatory defects, which
destroy the capillary endothelium and in particular the alve-
olar epithelium, plasma proteins transudate into the alveolar
space and activate coagulation, of which fibrin is the end
product.This is part of the natural healing and repair process
and serves as a primary occlusion of the membranous defect
[106].On the other hand, excessive and persistent coagulation
is pathologic and leads to fibrin deposition and fibrosis
formation, which has a negative impact on pathogenesis and
progression of multiple respiratory diseases [107, 108].
Apart from favoring fibrosis formation, fibrin and its
derivates influence pathomechanisms of inflammation and
the further course of the disease and repair of affected lung
tissue [109]. Fibrin stimulatesmigration of inflammatory cells
[110, 111] as well as adhesion and proliferation of fibroblasts
with following collagen production [112, 113]. The fibrin
molecule modulates the inflammatory response by binding
to monocytes and activation of transcription factors like NF-
𝜅B, which increases proinflammatory cytokine production
[114]. In addition, fibrin and its derivates inhibit surfac-
tant, decreasing the alveolar surface tension, favoring micro
atelectases, and decreasing gas exchange. This dysfunction
is caused by the inclusion of surfactant components into
the fibrin matrix and a following dysfunction of the main
phospholipid DPPC (Dipalmitoylphosphatidylcholine) [115].
Interactions of surfactant with fibrinogen, fibrin monomers,
and other proteins have also been demonstrated; of these
fibrin monomers have the strongest inhibitory effect [105].
It has been hypothesized early in human medicine that
respiratory disease damaging the alveolar membrane must
cause a misbalance between coagulatory and fibrinolytic
activity in the extravascular space. Studies on different
parameters of fibrinolysis like u-PA (urokinase-type plas-
minogen activator), PAI-1 (plasminogen activator inhibitor
1), and 𝛼
2
-AP (alpha 2-antiplasmin) and on d-dimers (a
fibrin-degradation product containing two D fragments of
the fibrin protein joined by a cross-link) have demonstrated
an increase in coagulation in bronchoalveolar lavage fluid
(BALF) in patients suffering from chronic respiratory disease
[106]. Coagulation and fibrinolysis have been shown to play
an important role in the pathomechanisms of numerous
pulmonary diseases in humans, and the development of ther-
apeutics supporting fibrinolysis is discussed as a promising
approach [116].
Increased coagulatory activity also influences airway
smooth muscle (ASM) proliferation. During asthma exac-
erbation, plasma circulating coagulant factor X (FX) enters
the inflamed airways and is activated (FXa). FXa, but not
FX, stimulated increases in ASM IL-6 production and cell
number [117].
In veterinary medicine and in particular in the equine
lung, literature in this field is rare so far. Nevertheless, thick-
ened alveolar interstitial spaces by the accumulation of fibrin
and fibrinogen have been found in horses affected by chronic
pulmonary disease [118]. In severe equine asthma, increased
concentrations of fibrinogen derivates, proteases, and pro-
coagulatory activity could be demonstrated in respiratory
secretions.The results of this study allow the assumption that
a misbalance of extravascular homeostasis is also a feature of
equine asthma and that fibrin deposition, following fibrosis
and surfactant dysfunction, supports the progression of the
disease. Fibrinolysis has been studied in more detail in other
organ systems, for example, in plasma and peritoneal fluid of
horses suffering from colic [119, 120] and in synovial fluid of
foals affected by arthritis [121].
5. Extracellular Remodeling
Remodeling of the extracellular matrix (ECM) of pulmonary
connective tissue is a continuous process allowing growth
and regeneration. To maintain the tissue’s stability, a balance
between degradation, in which matrix metalloproteinases
are the most important proteolytic enzymes, and resynthesis
of extracellular matrix structures is required [122]. The
pulmonary interstitium forms the mechanical scaffold of
the lung, while the basement membrane supports alveolar
epithelial cells and in part determines the resistance of the
diffusion barrier [123]. The primary structural fibrils of the
lung are composed of type I collagen and elastin. Elastin
fibers are very elastic and stable for a long time [124]. The
alveolar wall is primarily composed of type III collagen [125],
while the basement membrane is rich in type IV collagen.
Large collagen and elastin fibers are connected by a variety of
smaller fibrils. Degradation of the primary structural fibrils
of the lung will therefore involve cleavage of the cross-linking
fibrils to expose enzyme binding sites [126].Multiple enzymes
are involved in the turnover of the ECM and it may be
impossible to specify a single protease as the critical mediator
of any particular pulmonary disease.
The function of matrix metalloproteinases (MMPs) has
originally been described over fifty years ago [127]. MMPs
play an important role in the turnover of the extracellu-
lar matrix (ECM) components, tissue degradation, repair
mechanisms, and cell migration [128]. Their best known
physiological function is the cleavage and rebuilding of
connective tissues [129]. MMPs may play a crucial role in
inflammatory reactions by regulating physiologic barriers,
modulation of cytokines and chemokines, and establishing a
chemokine gradient to regulate the leukocyte accumulation
into the inflamed tissue [130].
MMPs are very likely to have a central role in destructive
pulmonary disease, characterized by fibrosis formation and
the loss of elastin and collagen fibers. Type I collagen
is very resistant against enzymatic degradation, which is
possible only by few specific MMPs at physiologic pH [131].
Some MMPs are elastases that may also degrade type IV
collagen [132]. Several studies have demonstrated a central
role of MMPs in chronic respiratory disease in humans
and horses. MMPs are assumed to be the major proteolytic
enzymes involved in the pathogenesis of COPD [133, 134].
Increased levels of MMP-1 and MMP-9 have been detected
in BALF of patients with emphysema, which are produced by
macrophages [135, 136].
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Several studies have been performed in horses, in which
MMPs were evaluated by zymography in BALF samples.
In severe equine asthma increased MMP-2 and MMP-9
concentrations were found compared to healthy controls
[137]. In particular MMP-9 seems to play a pathophysiologic
role [138]. Both MMP-2 and MMP-9 showed a correlation
to stable dust concentrations that contains fungal moulds
and bacterial endotoxins [139–141]. MMP-9 also correlated
to BALF neutrophilia and decreased with neutrophilia after
therapy [142].This was not found forMMP-2, which seems to
have a constitutive role in physiologic tissue remodeling [143].
Raulo et al. [144] were also unable to demonstrate increased
MMP-2 and MMP-14 activity in TW and BALF in severe
equine asthma, but up to 7 times increased activity ofMMP-9,
MMP-8, andMMP-13, produced by pulmonarymacrophages
and epithelial cells [144, 145].
It seems desirable to develop therapeutic approaches
that protect the lung against overwhelming MMP activity
but allow physiologic cell remodeling, which is important
in the immunology of healing processes [146]. To prevent
uncontrolled turnover of the ECM, inflammation, cellular
growth, and migration, MMP activity must be tightly con-
trolled on the levels of transcription, zymogen activity, and by
endogenous inhibitors. Overwhelming MMP activity in the
horse could be inhibited in vitro with doxycycline [143].
Tissue inhibitors ofmetalloproteinases (TIMPs) are natu-
ral, endogenousMMP-inhibitors that regulateMMP-induced
turnover of the ECM, tissue remodeling, and cellular behav-
ior [147, 148]. Next to several MMPs, TIMP-1 and TIMP-
2 were found to be increased in tuberculosis in humans
[149] and decreased after successful therapy. In COPD, local
MMP-9 and TIMP-1 concentrations in BALF were high,
while they were low in plasma [150]. In interstitial pneu-
mopathies MMP and TIMP patterns have been discussed
as possible prognostic markers and TIMP inhalation as a
possible therapeutic approach [151].There are some synthetic
inhibitors that regulate the pathologic effects of MMPs and
might support the healing process of epithelial membranes
in the airways [147, 148]. TIMP-1 and TIMP-2 levels as well as
MMP-TIMP ratios have also been studied in equine chronic
pneumopathies [138]. TIMP-1 and TIMP-2 concentrations
in BALF were significantly increased in all stages of equine
asthma compared to controls. In particular, the MMP-
8 : TIMP ratios were found useful to evaluate the severity
and character of respiratory disease andmay have prognostic
value for equine pneumopathies.
6. Airway Smooth Muscle Dysfunction
ASM hyperresponsiveness and hyperplasia are a well-known
phenomena in severe equine asthma [152]. In vitro and in
vivo studies have shown that the proliferative, secretory,
and contractile functions of airway smooth muscle (ASM)
are dysfunctional in human asthma. The same is true in
equine asthma [153], but ASM remodeling is not necessarily
associated with pulmonary neutrophilia and clinical status.
Leclere et al. [154, 155] found that inhaled corticosteroids
may accelerate the reversal of smooth muscle remodeling,
even if airway inflammation is better controlled with antigen
avoidance. Variousmediators are derived from inflammatory
cells or produced by ASM itself [156]. It has been shown that
ASM is not only an effector of bronchoconstriction, but has
additional roles as an immunomodulatory of inflammation
and remodeling. ASM can both produce and respond to an
array of cytokines, chemokines, and growth factors, leading
to cell migration and proliferation, production of ECM
proteins, and altered reactivity.
The roles of NF-𝜅ß and FXa have been discussed already.
Further key mediators in human asthma include CXC
chemokines,Th-17 derived cytokines, and semaphorins [156].
CXCL1, CXCL2, and CXCL3 are expressed by ASM, induce
neutrophil chemotaxis, and regulate ASM migration [156–
158].Th17-cells, a subset of T cells distinct fromTh1/Th2 cells,
produce IL-17 and IL-22. IL-17a contributes to human asthma
through recruitment of inflammatory cells including neu-
trophils, monocytes, and macrophages and by stimulation of
the release of MMPs as well as cytokines including IL-6 and
IL-8 [159–162]. Disease chronicity of equine asthma has also
been associated with Th17-mediated immunity [61, 163]. A
trend for upregulation of IL-17 was also found [164]. Th17
cytokines may therefore contribute to the sustained airway
neutrophilic inflammation in equine disease, as reported
in human asthma [165]. Semaphorins, previously called
collapsins, were initially discovered as “axon guidance” cues
in neuronal cells [166] but are now known to be ubiqui-
tously expressed. In human asthma, they also contribute
to inflammation, hyperresponsiveness, and remodeling by
regulating airway angiogenesis, recruitment of fibrocytes, and
promotion of myofibroblast hyperplasia [167, 168].
7. Conclusions
In conclusion, the results of the studies reviewed here show
the complexity in the pathogenesis of respiratory disease in
the horse. Many parallels can be drawn to human asthma, but
species specific differences have also been found. Therefore,
it is a challenge to find new therapeutic approaches to
these pathologies with a high economic impact in veterinary
medicine.Nevertheless, the numerous inflammatorymarkers
that have been established for horses so far may help to
understand the pathogenesis of lower airway disease in more
detail and to diagnose the different diseases correctly even in
subclinical cases. Further studies should focus on the course
of the evaluated markers during therapy to evaluate their use
in follow-up after therapy or during long-term therapy and
to evaluate the success of not only established, but also new
therapeutic approaches for chronic respiratory disease.
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